The FDA approved Corcept Therapeutics’ Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer—months ahead of its scheduled PDUFA date. The decision covers three cancer types in patients who have received up to three prior lines of therapy. Corcept positioned the oral, selective glucocorticoid receptor antagonist as a way to address endocrine-driven resistance biology in difficult-to-treat disease. Market reaction was immediate, with Corcept shares jumping after the agency’s earlier-than-planned clearance, strengthening the company’s effort to expand its commercial base in oncology.